Literature DB >> 29030334

Individualized Pazopanib Dosing-Letter.

Audrey Bellesoeur1,2,3, Pascaline Boudou-Rouquette1,2,3, Audrey Thomas-Schoemann4,3, Charlotte Joly5, Camille Tlemsani1,2,3, Michel Vidal6,3, François Goldwasser1,2,3, Benoit Blanchet6,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29030334     DOI： 10.1158/1078-0432.CCR-17-1873

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  1 in total

1.  Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients.

Authors:  Marie-Sophie Minot-This; Pascaline Boudou-Rouquette; Anne Jouinot; Sixtine de Percin; David Balakirouchenane; Nihel Khoudour; Camille Tlemsani; Jonathan Chauvin; Audrey Thomas-Schoemann; François Goldwasser; Benoit Blanchet; Jérôme Alexandre
Journal:  Pharmaceutics       Date:  2022-06-09       Impact factor: 6.525
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.